In this review, we will examine the double facets of BRAF gene alterations in different tumor types to highlight the clinical relevance of this biomarker not only in improving the pathological assessment of human solid neoplasms but also in facilitating treatment decision-making and outcomes. Here, BRAF is linked to neoplasm.